SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001731122-22-000700
Filing Date
2022-04-08
Accepted
2022-04-08 16:30:20
Documents
13
Period of Report
2022-04-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e3692_8-k.htm   iXBRL 8-K 28059
2 EXHIBIT 10.1 e3692_ex10-1.htm EX-10.1 20199
  Complete submission text file 0001731122-22-000700.txt   225317

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE avxl-20220407.xsd EX-101.SCH 2953
4 XBRL LABEL FILE avxl-20220407_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE avxl-20220407_pre.xml EX-101.PRE 22355
7 EXTRACTED XBRL INSTANCE DOCUMENT e3692_8-k_htm.xml XML 3607
Mailing Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163
Business Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163 800-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

IRS No.: 208365999 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37606 | Film No.: 22817395
SIC: 2836 Biological Products, (No Diagnostic Substances)